A Novel Score for Predicting Long‐Term Outcomes in Recanalisation‐Treated Patients With Budd‐Chiari Syndrome: A Multicentre Study
Liver International · 2025
DOI: 10.1111/liv.70259 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2025. Verfasst von Dongdong Xia und 31 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xij…. Hauptthemen laut MEDLINE: Budd-Chiari Syndrome, Angioplasty. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Boost Program of Xijing Hospital.
Abstract (Originalsprache)
Background and Aims A recanalisation‐specific model for Budd‐Chiari syndrome (BCS) is lacking. We aimed to develop a novel score for individual long‐term outcome prediction and risk stratification.
Methods
Overall, 834 BCS patients undergoing recanalisation (566 received percutaneous transluminal angioplasty alone, and 268 with routine stenting) from January 2010 to May 2019 were included from six Chinese centres. The model was developed using Cox multivariable regression, internally validated through a 1000‐times bootstrapped method, and compared its performance with existing BCS prognostic models, like the Clichy score.
Results
During the median follow‐up period of 58.0 months, 44 patients were converted to transjugular intrahepatic portosystemic shunt (TIPS), none underwent orthotopic liver transplantation (OLT) and 75 died. The final BCS‐Recanalisation score incorporated: variceal bleeding history, degree of ascites, albumin, creatinine, urea, white blood cell count and Ln (alkaline phosphatase). The score outperformed other available models with good discrimination (C‐index: 0.74) and calibration in predicting TIPS‐free survival in the whole cohort, internal validation and most subgroups. Moreover, patients were categorised as low‐risk (BCS‐Recanalisation score ≤ 2.0), intermediate‐risk (2.0–2.6) and high‐risk (> 2.6) groups using X‐tile software, with a 5‐year TIPS‐free survival rate of 92.2% (95% CI: 89.5%–95.0%), 84.7% (95% CI: 80.0%–90.0%) and 67.8% (95% CI: 59.4%–77.5%), respectively ( p < 0.001). Significant differences were observed in overall survival, stenting‐TIPS‐free survival and competing‐risk adjusted outcomes (restenosis, symptom recurrence, TIPS conversion) across risk strata.
Conclusions
The BCS‐Recanalisation score enables individualised outcome prediction and risk stratification in recanalisation‐treated patients with BCS, showing promise for clinical application. Future external validation is required.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers and National Clinical Research Center for Digestive Diseases, Xijing Hospital of Digestive Diseases, Fourth Military Medical University…
- Department of Liver Disease and Digestive Interventional Radiology, National Clinical Research Centre for Digestive Diseases and Xijing Hospital of Digestive Diseases, Fourth Military Medical University, Xi'an, China.
- Department of Digestive and Peripheral Vascular Interventional Radiology, Digestive Diseases Hospital, Xi'an International Medical Center Hospital, Northwest University, Xi'an, China.
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.
- Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University and to Shandong First Medical University, Jinan, China.
- Department of Vascular and Endovascular Surgery, Henan Provincial People's Hospital, Zhengzhou, China.
ORCID-Profile: Guangchuan Wang, Menghao Li, Yan Zhao, Guohong Han
Förderung
- National Natural Science Foundation of China
- The Boost Program of Xijing Hospital
Zitieren
APA
Xia, D., Luo, B., Wang, Q., Zhang, C., Zhang, K., Li, M., Fan, Q., Wang, Q., Bai, W., Li, K., Guo, W., Fan, J., Wang, G., Xiu, A., Wang, Z., Yuan, J., Lv, Y., Li, M., Li, B., …, & Han, G. (2025). A Novel Score for Predicting Long‐Term Outcomes in Recanalisation‐Treated Patients With Budd‐Chiari Syndrome: A Multicentre Study. Liver International. https://doi.org/10.1111/liv.70259
Vancouver
Xia D, Luo B, Wang Q, Zhang C, Zhang K, Li M, et al. A Novel Score for Predicting Long‐Term Outcomes in Recanalisation‐Treated Patients With Budd‐Chiari Syndrome: A Multicentre Study. Liver International. 2025. doi:10.1111/liv.70259
BibTeX
@article{Xia2025,
author = {Xia, Dongdong and Luo, Bohan and Wang, Qiuhe and Zhang, Chunqing and Zhang, Kewei and Li, Mingxing and Fan, Qingyong and Wang, Qiaozheng and Bai, Wei and Li, Kai and Guo, Wengang and Fan, Jiahao and Wang, Guangchuan and Xiu, Aiyuan and Wang, Zhengyu and Yuan, Jie and Lv, Yong and Li, Menghao and Li, Bing and Dong, Zenghui and Zhang, Na and Shang, Yiwei and Dai, Wei and Wang, Yalan and Tang, Hong and Yin, Zhanxin and Zhao, Yan and Xia, Jielai and Fan, Daiming and Xu, Ke and Wu, Kaichun and Han, Guohong},
title = {A Novel Score for Predicting Long‐Term Outcomes in Recanalisation‐Treated Patients With Budd‐Chiari Syndrome: A Multicentre Study},
journal = {Liver International},
year = {2025},
doi = {10.1111/liv.70259}
}
EUVIMED